Professional Documents
Culture Documents
Accepted Article
Article type : Original Research Article
Kim C. Danielsson 1 ,2 , Ingrid Borthen 2 , Nils Erik Gilhus 2 , 3 & Nils-Halvdan Morken 1 ,4
1
Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, 2Department of
Clinical Medicine, University of Bergen, Bergen, 3Department of Neurology, Haukeland University
Hospital, 4Department of Clinical Science, University of Bergen, Bergen, Norway.
Corresponding author:
Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway
E-mail: kim.christian.danielsson@helse-bergen.no
Disclosure of interests:
This article has been accepted for publication and undergone full peer review but has not
been through the copyediting, typesetting, pagination and proofreading process, which may
lead to differences between this version and the Version of Record. Please cite this article as
doi: 10.1111/aogs.13360
Introduction: Women with epilepsy have increased risk of complications in pregnancy with
Accepted Article
consequences for the mother and child. There are no studies on the influence of parity on
complications in women with epilepsy.
Material and methods: This was a population-based cohort study of all first and second births in the
Medical Birth Registry of Norway 1999-2013. Risks were estimated, and complication rates
compared in distinct women with epilepsy treatment categories. Outcomes were any hypertensive
disorder, bleeding in pregnancy, induction of labour, cesarean section, postpartum hemorrhage and
preterm birth.
Results: We examined 361 588 women, of whom 211 248 had a second birth and 1074 (0.5 %) of
these had a diagnosis of epilepsy in both births. Of these, 406 used antiepileptic drugs in both
pregnancies with, lamotrigine (N=118), carbamazepine (N=83), valproate (N=44), and levetiracetam
(N=27) being the four most common monotherapies. In the second birth, only risk of elective
cesarean section (adjusted OR = 1.7, 95% CI: 1.4 -2.0) and induction of labour (adjusted OR = 1.5,
95% CI: 1.2 -1.7) were increased in women with epilepsy compared to women without epilepsy.
There was a significant reduction in any hypertensive disorder, mild preeclampsia, emergency
cesarean section, postpartum hemorrhage (>500ml), and preterm birth from first to second birth in
women with epilepsy, and also a significant increase in elective cesarean section.
Conclusions: Second births in women with epilepsy do not represent an increased risk of non-
iatrogenic complications, independent of antiepileptic drug use. There is a significant reduction in
complications from first to second births in women with epilepsy.
Keywords
Key message
Parity has a significant effect on risks of pregnancy and obstetric complications in women with
epilepsy. Only the iatrogenic interventions elective cesarean section and induction of labour was
increased in second births in a non-selected national cohort of women with epilepsy. Women with
epilepsy follow a similar pattern as women without epilepsy with a reduced risk of pregnancy and
obstetric complications from first to second birth.
Introduction
Epilepsy is the most common neurologic disorder requiring continuous drug treatment during
pregnancy, and 30 - 70% of pregnant women with epilepsy (WWE) use antiepileptic drugs (AEDs).(1-4)
WWE, and WWE with AEDs in particular, have previously been described as high risk parturients
with an increased rate of obstetric complications such as; bleeding in pregnancy, hypertensive
pregnancy disorders, induction of labour, cesarean section, postpartum hemorrhage and preterm
delivery.(5-9) Guidelines and review articles have highlighted focused management and individual
assessment for WWE in pregnancy to improve maternal morbidity and mortality.(7, 10-12)
Complications in WWE imply possible consequences for the mother and her child and may affect
reproductive intentions for some women.(13, 14) Pregnancy and obstetric complications increase risks
for recurrence next time, and also affect risks for new complications in later pregnancies.(13-18) Thus,
subsequent pregnancies in the same woman are not independent events, and results from previous
cross-sectional studies not taking this into account should be interpreted with caution.
Studies have focused on consequences of epilepsy and maternal AED use during pregnancy for fetal
malformations and child development.(21-24) In contrast, potential effects of epilepsy and specific
AEDs on pregnancy have been much less studied. Optimal therapy in epilepsy represents a balance
between seizure suppression and AED side-effects. For women in fertile age, potential AED effects
for the fetus as well as on the pregnancy should be of the highest relevance. It is necessary to
estimate the specific effect of parity on complications in WWE with and without AEDs in order to
give WWE optimal treatment and advice in preconceptional counselling.
Our aim was to estimate risks in first and second pregnancy and birth, and to estimate the effect of
parity on changes in risks and recurrence rates for hypertensive pregnancy disorders, bleeding in
pregnancy, induction of labour, cesarean section, postpartum hemorrhage and preterm delivery in
WWE. The effect of AEDs in monotherapy was defined, and WWE were compared to women
without epilepsy.
We used population-based data from the Medical Birth Registry of Norway (MBRN) during 1999-
2013. A unique social security number given to all citizens in Norway enables linkage of data from
various national data sources and all births to the same mother (sibship data). Linked data from the
National Population Database ensures notification of all births and deaths in the country. Reporting
to the MBRN is compulsory and data are prospectively registered throughout pregnancy, delivery
and postpartum period on an unchanged form since 1999. All data are forwarded to the MBRN by
the attending midwife or obstetrician. Data includes maternal and paternal social factors, maternal
The Norwegian Prescription Database (NorPD, commenced in 2004) provided detailed data on all
medications dispensed from pharmacies by prescription. Mandatory registration in NorPD of every
dispensed medical prescription is made by a pharmacist. Statistics Norway provided data on
maternal level of education.
Exposure variables were a diagnosis of epilepsy at both births and the use of AEDs in both
pregnancies. Maternal epilepsy was registered in a specific checkbox or by adding written text in a
blank space available at the MBRN form. Information on type of epilepsy or seizure activity was not
available. The epilepsy diagnosis in MBRN has previously been found to be valid in 92.3 % of cases.(3)
Information on AED use in pregnancy (identified by ATC classification) was recorded as written text
with no information on dose or therapeutic changes over time. We analyzed total AED use and the
four most common AEDs in monotherapy, this to obtain both homogenous and large enough groups.
Monotherapy was defined as using the same single AED in the first and second pregnancy. Linkage
to NorPD enabled validation of the AED registration in the MBRN, (data available 2004 - 2012).
Main outcomes in the first and second births were; a compound variable of any hypertensive
disorder in pregnancy, mild- and severe preeclampsia, bleeding in pregnancy, induction of labour at
term, emergency and elective cesarean section, postpartum hemorrhage (>500ml and >1500ml),
and spontaneous preterm birth. Spontaneous preterm birth, < 37 weeks, (induction of labour and
preterm elective cesarean sections were excluded from analyses) was calculated from ultrasound
assessment of due date or last menstrual period (ultrasound dates were missing in 4251 women, 2.0
% of births). The compound variable of any hypertensive disorder included occurrence of gestational
hypertension, mild preeclampsia (blood pressure ≥140/90 mmHg combined with proteinuria ≥ 0,3g
per 24 hours) or severe preeclampsia (blood pressure ≥160/110mmHg, protein excretion ≥3 g per 24
Other variables were: maternal age (≤19 years, 20-24 years, 25-29 years, 30-34 years, 35-39 years
and ≥40 years), maternal education (≤10 years, 11-13 years, ≥14 years), chronic disease (kidney
disease, hypertension, diabetes mellitus), multifetal pregnancies, high body mass index (BMI
≥30kg/m²), smoking during pregnancy, use of folic acid supplementation in standard dose
(0,4mg/day), inter-delivery interval (inter-delivery interval: > 6 years), augmented contractions in
labour, vaginal operative delivery (vacuum or forceps), and placenta previa. BMI was available from
2006 onwards. Data on ethnicity and marital status were not available due to ethical restrictions.
Statistical analyses
All WWE were compared to all women without epilepsy. Risk of the various outcomes in first and
second births were estimated by treatment category i.e. WWE with and without AED, and by the
four most common monotherapies. Changes in risks from first to second birth and recurrence rates
were estimated in treatment categories. The recurrence rates in WWE and women without epilepsy
were compared.
We estimated proportions and crude odds ratios (ORs) using contingency tables. P-values were
calculated by Fisher’s exact test and independent sample t-tests, where appropriate. We used
logistic regression to adjust for possible confounding by maternal age, educational level, multifetal
pregnancy, and chronic diseases (pre-existing hypertension, kidney disease, and diabetes mellitus)
for all outcomes. Furthermore adjustment by interdelivery-interval, induction of labour, placenta
previa, caesarean section, augmented contractions, operative vaginal delivery, and vaginal bleeding
Ethical approval
The study was approved by the Regional Ethics Committee (REK 2013/186) and the Norwegian Data
Protection Authority.
Results
During the study period 361 588 women gave birth, of whom 211 248 had a second birth. There
were 1074 (0.5 %) women with registered epilepsy at both births. Maternal characteristics are
presented in Table 1. WWE had significantly longer inter-delivery interval, and significantly fewer
had the same partner in the second birth compared to women without epilepsy. A second
pregnancy was registered in 38.0 % of WWE compared to 58.6 % of women without epilepsy (p-
value < 0.005). 326 WWE used the same specified AED in monotherapy in both pregnancies, and the
four most common drugs were: lamotrigine (118 women), carbamazepine (83 women), valproate
(44 women), and levetiracetam (27 women). The use of AED, AED polytherapy and treatment
changes between the two births are reported in Table 2.
All first births were analyzed separately (see Supporting Information Table S1). We found increased
risks of any hypertensive disorder, mild preeclampsia, induction of labour, all and elective cesarean
section, bleeding in pregnancy, and preterm birth in WWE compared to women without epilepsy.
First births of WWE who had a subsequent birth were compared to those with only one birth in the
study period. WWE with only one birth had a significantly higher risk for preterm birth, but
otherwise there were no significant differences.
Prevalence of outcomes in WWE changed from the first to the second birth similar to the changes
seen in women without epilepsy (Figure 1). When the first and second births of WWE were
compared within treatment categories, the reduction in risk was significant for any hypertensive
disorder, mild preeclampsia, emergency cesarean section, and postpartum hemorrhage (>500ml) in
total WWE, WWE with and WWE without AEDs (Table 4). For preterm birth and severe preeclampsia
the reduction was significant in WWE and WWE without AED. The risk of elective cesarean section
increased significantly from the first to the second birth in WWE, WWE with and without AED. All
changes in outcome risks from the first to the second birth were significant also in women without
epilepsy.
In WWE the recurrence rate of any hypertensive disorder was 21.4 %, whereas the prevalence of any
hypertensive disorder in the second birth without preceding occurrence was only 2.7 %. Thus the
risk of recurrence was highly significant (aOR = 10.3, 95% CI: 5.5-19.6) (Supporting Information Table
S3). Similarly, the recurrence rate of all complications, except postpartum hemorrhage and severe
preeclampsia, was significantly increased in WWE, WWE with and without AEDs. In women without
epilepsy, the risk of recurrence was also significantly increased for all outcomes. When the risk of
recurrent complications in WWE was compared with women without epilepsy, only induction of
labour and elective cesarean section was increased for WWE (Supporting Information Table S4).
AED use as recorded in MBRN, was validated by a corresponding prescription in NorPD during the
pregnancy. The positive predictive values were: 91.7 % for all AEDs, 86.3 % for lamotrigine, 86.7 for
carbamazepine, 88.2 % for valproate and, 94.4 % for levetiracetam.
Discussion
WWE have in their second pregnancy and birth no increased risk of any hypertensive disorder, mild
or severe preeclampsia, vaginal bleeding in pregnancy, preterm birth, emergency cesarean section,
or postpartum hemorrhage compared to women without epilepsy. This was true for WWE in general
as well as for WWE on the most common AED monotherapies. This finding contrasts previous
studies, where increased pregnancy risks have been found for WWE.(5-8) Our study shows that the
increased risk occurs for the first, but not for the subsequent birth. This was confirmed by our
observation of a significant risk reduction from the first to the second birth in WWE. This risk
reduction in WWE showed a similar pattern as for women without epilepsy.
We found significant impact of parity on complications in WWE in two dimensions; when compared
to women without epilepsy and when comparing first to the second birth in WWE. The present study
shows increased risks of complications in the first birth in WWE in line with previous results.(5-8) In
the second birth, complications occurred with the same frequency as in WWE without AED and in
women without epilepsy. As WWE had a similar risk change as women without epilepsy from first to
second birth, non-epilepsy factors are important for risk development in WWE.
The risk of elective cesarean section and induction of labour in WWE both with and without AEDs
remained increased for the second birth, and the risk of recurrence was increased compared to
women without epilepsy. Elective cesarean section and induction of labour are both interventions
decided by physicians, with consent from the patient, with the aim to end the pregnancy before or
This study represents a selected epilepsy population since the included women have given birth at
least two times, thereby possibly excluding those with severe complications and severe cases of
epilepsy in women who would choose not to repeat a pregnancy. Seizure frequency, lifestyle, or
socioeconomic status that encourages subsequent pregnancies in WWE is expected to affect risks
also in the second pregnancy. However, background data for WWE with subsequent births in this
study did not differ from the same nullipara population, with the exception of less obesity in women
who had a second birth. Major complications among WWE with only one birth did not differ from
WWE with subsequent pregnancies. Thus it is not likely that obstetric complications have been a
reason for ending reproduction in WWE. Seizure activity and adverse fetal outcomes can possibly
influence a choice of further reproduction in WWE. Our study was not able to examine such
associations.
Our large and unselected nationwide cohort enabled assessment of complications in first and second
birth separately, and risks associated with the most common AEDs in monotherapy. The sib-ship
structure of our data enabled us to account for the obvious dependence between two births from
the same woman. The standardized data collection provided information of high validity.(3) The study
The MBRN does not register seizure activity or type of epilepsy, this being a limitation of our study.
However, a previous study did not find any association between seizure activity and complications in
pregnancy.(3) WWE with specified AED monotherapy had low frequencies of most complications,
and therefore our study lacks strength for several variables despite our large cohort of pregnant
women. We lacked information on ethnicity and marital status which were not released due to
ethical considerations.
We found a significant reduction in risk of pregnancy and obstetric complications from first to
second pregnancy in WWE. Second pregnancies in WWE did not have any increased risk of
complications. Only the iatrogenic interventions, induction of labour and elective cesarean section
were increased in second births. These interventions also had an increased risk of recurrence in
WWE compared to women without epilepsy. This suggests that the epilepsy alone is not the reason
for the increase in complications seen in first pregnancies in WWE, as the epilepsy and AED
treatment remained unchanged from first to second pregnancy. The reduction of complications was
also seen in women without epilepsy. However, the reduction of complications in WWE was so
pronounced that there was no longer any difference between WWE and women without epilepsy at
the second pregnancy and birth. The reduction in obstetric complications, to the level seen in
women without epilepsy, is important and should be considered in all individual risk assessments,
and counselling, of WWE.
Acknowledgements
We are grateful for data provision and linkage that was performed by Medical Birth Registry of
Norway, Norwegian Prescription Database and Statistics Norway.
This research was kindly supported by the Fund of Torbjørg Hauge’s Legacy.
Accepted Article
References
1. Artama M, Gissler M, Malm H, Ritvanen A, Drug and Pregnancy Group. Effects of maternal
epilepsy and antiepileptic drug use during pregnancy on perinatal health in offspring: nationwide,
retrospective cohort study in Finland. Drug safety. 2013;36(5):359-69.
2. Borthen I, Eide MG, Veiby G, Daltveit AK, Gilhus NE. Complications during pregnancy in
women with epilepsy: population-based cohort study. BJOG. 2009;116(13):1736-42.
3. Borthen I, Eide MG, Daltveit AK, Gilhus NE. Obstetric outcome in women with epilepsy: a
hospital-based, retrospective study. BJOG. 2011;118(8):956-65.
5. Borthen I, Gilhus NE. Pregnancy complications in patients with epilepsy. Curr Opin Obstet
Gynecol. 2012;24(2):78-83.
7. MacDonald SC, Bateman BT, McElrath TF, Hernandez-Diaz S. Mortality and Morbidity During
Delivery Hospitalization Among Pregnant Women With Epilepsy in the United States. JAMA
neurology. 2015;72(9):981-8.
8. Kilic D, Pedersen H, Kjaersgaard MI, Parner ET, Vestergaard M, Sorensen MJ, et al. Birth
outcomes after prenatal exposure to antiepileptic drugs--a population-based study. Epilepsia.
2014;55(11):1714-21.
9. Al Wattar BH, Tamilselvan K, Khan R, Kelso A, Sinha A, Pirie AM, et al. Development of a core
outcome set for epilepsy in pregnancy (E-CORE): a national multi-stakeholder modified Delphi
consensus study. BJOG. 2017;124(4):661-7.
12. Harden C, Thomas SV, Tomson T (Editors). Epilepsy in Women. Somerset, NJ, USA: John
Wiley & Sons; 2013.
13. Hemminki E, Shelley J, Gissler M. Mode of delivery and problems in subsequent births: a
register-based study from Finland. Am J Obstet Gynecol. 2005;193(1):169-77.
15. Ebbing C, Rasmussen S, Skjaerven R, Irgens LM. Risk factors for recurrence of hypertensive
disorders of pregnancy, a population-based cohort study. Acta Obstet Gynecol Scand.
2017;96(2):243-50.
16. Al-Zirqi I, Vangen S, Forsen L, Stray-Pedersen B. Effects of onset of labor and mode of
delivery on severe postpartum hemorrhage. Am J Obstet Gynecol. 2009;201(3):273 e1-9.
17. Laughon SK, Albert PS, Leishear K, Mendola P. The NICHD Consecutive Pregnancies Study:
recurrent preterm delivery by subtype. Am J Obstet Gynecol. 2014;210(2):131 e1-8.
18. Lykke JA, Paidas MJ, Langhoff-Roos J. Recurring complications in second pregnancy. Obstet
Gynecol. 2009;113(6):1217-24.
19. Danielsson K, Borthen I, Morken NH, Gilhus NE. Hypertensive pregnancy complications in
women with epilepsy and antiepileptic drugs: a population-based cohort study of first pregnancies in
Norway. BMJ Open. 2018;In press.
20. Wilcox AJ. The analysis of recurrence risk as an epidemiological tool. Paediatr Perinat
Epidemiol. 2007;21 Suppl 1:4-7.
23. Gerard EE, Meador KJ. Managing Epilepsy in Women. Continuum. 2016;22(1 Epilepsy):204-
26.
24. Tomson T, Xue H, Battino D. Major congenital malformations in children of women with
epilepsy. Seizure. 2015;28:46-50.
25. RCOG. Epilepsy in Pregnancy (Green-top Guidlines No. 68) 2016 [cited 2017]. Available from:
https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg68/.
26. Battino D, Tomson T, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Seizure control and
treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry.
Epilepsia. 2013;54(9):1621-7.
Table S1. Complications in first birth of women with epilepsy women with epilepsy with and without
antiepileptic drugs (1999-2013).
Table S2. Complications in second births of women with epilepsy with specified antiepileptic drug
monotherapies compared to women without epilepsy.
Table S3. Recurrence in second births conditioned on the same complication in the first birth,
comparison of women with epilepsy with women without epilepsy.
Figure 1. Prevalence of complications in first and second birth for women with and without epilepsy.
Accepted Article
The figure shows prevalence (in percent) of complications in 361 588 first births and in 211 248
consecutive second births from the same women. Complications are defined in women with epilepsy
(WWE), WWE with and without antiepileptic drugs (AEDs), and women without epilepsy. Statistics
and comparisons in the first births, the second births, and changes from the first to the second births
are also shown in Supporting Information Table S1, Table 3, and Table 4 respectively.
Table 2. Antiepileptic drug use in first and second birth of 1074 women with epilepsy, Medical Birth
Registry of Norway 1999-2013.
Table 3. Complications in second births of women with epilepsy (WWE) with and without
antiepileptic drugs (AEDs) compared to women without epilepsy.
Table 4. Change in prevalence from first to second birth in women with epilepsy (WWE) with and
without antiepileptic drugs (AEDs).
INTERDELIVERY INTERVAL
Months 37.3 39.2 <0.005
>6 years 13485 (6.4) 79 (7.4) 0.195
EDUCATION
≤10 years 27474 (13.0) 202 (18.8) <0.005
11-13 years 144801 (68.6) 760 (70.8) 0.124
≥ 14 years 26015 (12.3) 69 (6.4) <0.005
Other or missing 12858 (6.1) 43 (4.0) <0.005
PLURALITY
Multifetal 3486 (1.7) 10 (0.9) 0.064
GESTATIONAL AGE
Weeks + days 39+5 39+4 0.025
BIRTH WEIGHT
Mean (gram) 3606 3577 0.085
2
BMI >30 kg/m
(from year 2006, N =148748) 7090 (12.9) 46 (13.2) 0.869
Missing data 92953 (62.8) 420 (54.6) <0.005
SMOKING
Yes 19586 (9.3) 148 (13.8) <0.005
Missing data 36758 (17.4) 165 (15.4) 0.078
CHRONIC DISEASE
(Kidney disease, DM, HT) 3280 (1.6) 30 (2.8) 0.001
FOLIC ACID
Before Pregnancy 54732 (25.9) 419 (39.0) <0.005
During Pregnancy 126236 (59.8) 793 (73.8) <0.005
SAME PARTNER
(First and second pregnancy) 192778 (91.3) 946 (88.1) <0.005
N % of WWE
Accepted Article
Without AEDs in both birthsa 470 43.8
Any AED in both birthsa 406 37.8
Discontinuing AEDs from first to second birtha 107 10.0
Any AED only in second birtha 91 8.4
Same AED monotherapy in both births 326 30.4
Lamotrigine monotherapy in both births 118 11.0
Carbamazepine monotherapy in both births 83 7.7
Valproate monotherapy in both births 44 4.1
Levetiracetam monotherapy in both births 27 2.5
Other AED monotherapies in both birthsb 54 5.0
Any AED polytherapy in both births 44 4.1
Change of AED treatment between births 36 3.4
Women without
WWE WWE without AED WWE with AED
Epilepsy
N= 211 248 N=210 174 N=1074 N=470 N=406
N (% ± 2SE) N (% ± 2SE) aOR 95% CI N (% ± 2SE) aOR 95% CI N (% ± 2SE) aOR 95% CI
a
Any Hypertensive Disorder 7754 (3.7 ± 0.08) 47 (4.4 ± 1.24) 1.19 0.89-1.59 13 (2.8 ± 1.52) 0.74 0.43-1.29 19 (4.7 ± 2.10) 1.26 0.79-2.00
a
Mild Preeclampsia 3037 (1.4 ± 0.06) 22 (2.0 ± 0.86) 1.41 0.92-2.15 8 (1.7 ± 1.20) 1.17 0.58-2.34 9 (2.2 ± 1.46) 1.52 0.78-2.94
a
Severe Preeclampsia 1599 (0.8 ± 0.04) 9 (0.8 ± 0.56) 1.10 0.57-2.12 3 (0.6 ± 0.74) 0.83 0.27-2.60 5 (1.2 ± 1.10) 1.63 0.67-3.95
Induction of Labour 21378 (11.2 ± 0.14) 152 (15.8 ± 2.36) 1.46 1.22-1.73 49 (11.5 ± 3.08) 0.99 0.73-1.34 67 (18.6 ± 4.10) 1.79 1.37-2.33
b
Emergency Cesarean Section 13818 (6.6 ± 0.10) 77 (7.2 ± 1.48) 1.04 0.82-1.31 30 (6.4 ± 2.26) 0.93 0.64-1.35 37 (9.1 ± 2.86) 1.31 0.93-1.84
Elective Cesarean Section 14429 (6.9 ± 0.12) 120 (11.2 ± 1.92) 1.65 1.36-2.01 50 (10.6 ± 2.84) 1.60 1.19-2.15 49 (12.1 ± 3.24) 1.72 1.27-2.33
c
Bleeding in Pregnancy 9577 (4.6 ± 0.10) 50 (4.7 ± 1.28) 1.01 0.76-1.34 24 (5.1 ± 2.04) 1.12 0.74-1.69 20 (4.9 ± 2.16) 1.10 0.70-1.72
d
PPH > 500ml 27489 (13.1 ± 0.14) 155 (14.4 ± 2.14) 1.00 0.84-1.20 52 (11.1 ± 2.90) 0.76 0.57-1.03 66 (16.3 ± 2.66) 1.09 0.83-1.43
d
PPH > 1500ml 3268 (1.6 ± 0.06) 18 (1.7 ± 0.78) 0.98 0.62-1.57 7 (1.5 ± 1.12) 0.92 0.43-1.94 7 (1.7 ± 1.30) 0.95 0.45-2.02
e
Preterm Birth 7047 (4.2 ± 0.10) 34 (4.5 ± 1.50) 1.06 0.75-1.52 13 (3.6 ± 1.98) 0.87 0.50-1.53 14 (5.2 ± 2.70) 1.27 0.73-2.21
± 2SE: 2 x Standard Error, representing upper and lower limit of 95% confidence interval (CI)
All outcomes are adjusted for: Maternal age, Educational level, Multifetal pregnancy, and other relevant chronic disease
a
Also adjusted for: Long interdelivery interval.
b
Also adjusted for: Induction of Labour.
c
Also adjusted for: Placenta previa.
d
Also adjusted for: Induction of Labor, Cesarean Section, Augmented Contractions, and Operative Vaginal Delivery.
e
Also adjusted for: Vaginal Bleeding in Pregnancy.
Women without epilepsy WWE WWE without AED WWE with AED
N = 358761/ N = 210174 N = 2827/ N = 1074 N = 1774/ N = 470 N = 1053/ N = 406
a
Mild Preeclampsia 3.2% / 1.4% 0.45 0.43-0.46 4.6% / 2.0% 0.43 0.28-0.69 4.3% / 1.7% 0.38 0.18-0.80 5.0% / 2.2% 0.43 0.21-0.88
a
Severe Preeclampsia 2.1% / 0.8% 0.36 0.35-0.38 2.4% / 0.8% 0.34 0.17-0.69 2.6% / 0.6% 0.24 0.08-0.78 2.1% / 1.2% 0.58 0.22-1.55
c
Bleeding in Pregnancy 4.7% / 4.6% 0.97 0.95-1.00 5.6% / 4.7% 0.82 0.59-1.13 5.9% / 5.1% 0.86 0.54-1.35 5.1% / 4.9% 0.96 0.57-1.62
d
PPH > 1500ml 2.1% / 1.6% 0.74 0.71-0.77 2.4% / 1.7% 0.70 0.42-1.19 2.2% / 1.5% 0.67 0.30-1.51 2.7% / 1.7% 0.64 0.28-1.48
e
Preterm Birth 6.8% / 4.2% 0.61 0.59-0.62 8.7% / 4.5% 0.49 0.34-0.72 8.8% / 3.6% 0.39 0.22-0.70 8.4% / 5.2% 0.60 0.33-1.09
All outcomes are adjusted for: Maternal age, Educational level, Multifetal pregnancy, and other relevant chronic disease
a
Also adjusted for: Long interdelivery interval.
b
Also adjusted for: Induction of Labour.
c
Also adjusted for: Placenta previa.
d
Also adjusted for: Induction of Labor, Cesarean Section, Augmented Contractions, and Operative Vaginal Delivery.
e
Also adjusted for: Vaginal Bleeding in Pregnancy.
20 20 8
15 15 6
10 10 4
5 5 2
0 0 0
First Second First Second First Second
Women without Epilepsy: WWE: WWE without AED: WWE with AED:
Figure 1. Prevalence of complications in first and second birth for women with and without epilepsy.
The figure shows prevalence (in percent) of complications in 361 588 first births and in 211 248 consecutive second births from the same women. Complications are
defined in women with epilepsy (WWE), WWE with and without antiepileptic drugs (AEDs), and women without epilepsy. Statistics and comparisons in the first births, the
second births, and changes from the first to the second births are also shown in Table S1, Table 3, and Table 4 respectively.